$6.41 0.00 (0.00%)

Tenax Therapeutics, Inc. (TENX)

Tenax Therapeutics, Inc. is a pharmaceutical company focused on developing targeted therapies for critical and serious respiratory and cardiovascular conditions. It is known for its development of inhaled drugs designed to improve outcomes for patients with pulmonary hypertension and other life-threatening diseases. The company's pipeline emphasizes innovative solutions to address unmet medical needs in these areas.

🚫 Tenax Therapeutics, Inc. does not pay dividends

Company News

Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025
GlobeNewswire Inc. • Tenax Therapeutics • August 28, 2025

Tenax Therapeutics will participate in the Cantor Global Healthcare Conference 2025, presenting a fireside chat about their ongoing Phase 3 LEVEL Study for pulmonary hypertension treatment, with patient enrollment expected in first half of 2026.

Trump's Federal Spending Freeze Puts $3 Trillion In Limbo, Threatens Industries Like Clean Energy, Defense, Health Care
Benzinga • Piero Cingari • January 28, 2025

The White House has ordered a temporary freeze on all federal grants and loans, putting $3 trillion in funding under scrutiny and threatening industries like clean energy, defense, and healthcare.

Zacks.com featured highlights Universal Health Services, Tenet Healthcare Corp., Century Communities and Magnite
Zacks Investment Research • Zacks.Com • August 2, 2024

The article highlights four stocks - Universal Health Services, Tenet Healthcare Corp., Century Communities, and Magnite - that are trading near their 52-week highs and are expected to maintain their momentum and keep scaling new highs.

5 Hot Penny Stocks To Watch With Big News This Week
PennyStocks • J. Samuel • May 31, 2023

Penny stocks to watch with news this week. The post 5 Hot Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What You Might Have Missed: Warren Buffett's Biggest and Brightest
Investing.com • Brenda O'Farrell/Investing.com • November 20, 2022